A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Study Overview
=================
Brief Summary
-----------------
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

Detailed Description
-----------------
Phase 1 Dose-Finding Is the open-label dose-finding portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study. The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group. Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose. Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to <5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to <12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the third dose of BNT162b2 will be based on age at the time of vaccination: participants <5 years of age at the time of the third dose will receive the 3-µg dose level, participants ≥5 to <12 years of age at the time of the third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the third dose will receive the 30-µg dose level. Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the selected BNT162b2 dose level for Phase 2/3. Participants will also have blood drawn prior to Dose 3 and 1, 6, and 12 months after Dose 3. Phase 2/3 Selected-Dose Is the portion of the study that will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from the Phase 1 dose-finding portion of the study. Efficacy will be evaluated within or across age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases in those age groups. Participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at (1) baseline and 1 month after Dose 2 and (2) baseline and 1 month after Dose 3. The persistence of the immune response will be based on immunogenicity data collected in participants at (1) baseline and 1 and 6 months after Dose 2 and (2) baseline and 1, 6, 12, and 18 months after Dose 3. In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed in participants ≥5 to <12 years of age. At designated US sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. Additional samples will be obtained prior to Dose 3 and 1 month after Dose 3 (original BNT162b2 group only). These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points. At the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study. Participants who originally received placebo and become eligible for receipt of BNT162b2 or another COVID-19 vaccine according to local or national recommendations prior to the 6 month follow-up visit (Visit 5 or 405) (detailed separately and available in the electronic study reference portal) will have the opportunity to receive BNT162b2 (10 µg or 3 µg) based on age at the time of vaccination. Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to <5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to <12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants <5 years of age at the time of the second/third dose will receive the 3-µg dose level, participants ≥5 to <12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level. Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing If testing of troponin I levels in individuals who did not receive BNT162b2 indicates that troponin I level could be a reliable indicator of potential subclinical myocarditis, obtaining serum samples for potential troponin I testing during the period of increased risk of clinical myocarditis may help characterize the absence/presence and frequency of subclinical myocarditis. To assess, an additional group of participants will be included: ≥5 to <12 years: randomized 2:1 to receive BNT162b2 10 µg or placebo, and ≥12 to <16 years of age: open-label receipt of BNT162b2 30 µg. Update as part of protocol amendment 7: All participants will receive a third dose of BNT162b2. For all participants (≥5 to <12 and ≥12 to <16 years of age), the third dose will occur at least 5 months after Dose 2. The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants ≥5 to <12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level. Update as part of protocol amendment 8: The Lower-Dose Evaluation portion of the protocol has been removed. Participation in the study will cease 6 months after the third dose of BNT162b2.

Official Title
-----------------
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN

Conditions
-----------------
SARS-CoV-2 Infection, COVID-19

Intervention / Treatment
-----------------
* Biological: Biological/Vaccine: BNT162b2 10mcg
* Biological: BNT162b2 20mcg
* Biological: BNT162b2 30mcg
* Other: Placebo
* Biological: Biological/Vaccine: BNT162b2 3mcg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Male or female participants ≥6 months to <12 years of age, at the time of randomization, at Visit 1 for the dose-finding/selected-dose evaluation. For the obtaining-serum-samples-for-potential-troponin I-testing portion of the study: Male or female participants between ≥5 and <16 years of age. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation. Negative urine pregnancy test for female participants who are biologically capable of having children. Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children. The participant or participant's parent(s)/legal guardian is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written). Exclusion Criteria Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19. Phase 1 only: Known infection with HIV, HCV, or HBV. Receipt of medications intended to prevent COVID-19. Previous or current diagnosis of MIS-C. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. Female who is pregnant or breastfeeding. Previous vaccination with any coronavirus vaccine. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. Previous participation in other studies involving study intervention containing LNPs. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low/Mid-Dose, ≥5 to <12 Years<br>Low/Mid-Dose (10mcg), 2 doses 21 days apart | Biological: Biological/Vaccine: BNT162b2 10mcg<br>* BNT162b2 Low/Mid-Dose (10mcg) level<br>|
| Experimental: Mid-Dose, ≥5 to <12 Years<br>Mid-Dose, (20mcg), 2 doses 21 days apart | Biological: BNT162b2 20mcg<br>* BNT162b2 Mid-Dose (20mcg) level<br>|
| Experimental: High-Dose, ≥5 to <12 Years<br>High-Dose (30mcg), 2 doses 21 days apart | Biological: BNT162b2 30mcg<br>* BNT162b2 High-Dose (30mcg) level<br>|
| Experimental: Low/Mid-Dose, ≥2 to < 5 Years<br>Low/Mid-Dose (10mcg), 2 doses 21 days apart | Biological: Biological/Vaccine: BNT162b2 10mcg<br>* BNT162b2 Low/Mid-Dose (10mcg) level<br>|
| Experimental: Mid-Dose, ≥2 to <5 Years<br>Mid-Dose, (20mcg), 2 doses 21 days apart | Biological: BNT162b2 20mcg<br>* BNT162b2 Mid-Dose (20mcg) level<br>|
| Experimental: High-Dose, ≥2 to <5 Years<br>High-Dose, (30mcg), 2 doses 21 days apart | Biological: BNT162b2 30mcg<br>* BNT162b2 High-Dose (30mcg) level<br>|
| Experimental: Low/Mid-Dose, ≥6 Months to <2 Years<br>Low/Mid-Dose, (10mcg), 2 doses 21 days apart | Biological: Biological/Vaccine: BNT162b2 10mcg<br>* BNT162b2 Low/Mid-Dose (10mcg) level<br>|
| Experimental: Mid-Dose, ≥6 Months to <2 Years<br>Mid-Dose, (20mcg), 2 doses 21 days apart | Biological: BNT162b2 20mcg<br>* BNT162b2 Mid-Dose (20mcg) level<br>|
| Experimental: High-Dose, ≥6 Months to <2 Years<br>High-Dose, (30mcg), 2 doses 21 days apart | Biological: BNT162b2 30mcg<br>* BNT162b2 High-Dose (30mcg) level<br>|
| Placebo Comparator: Placebo, ≥6 Months to <2 Years<br> | Other: Placebo<br>* Intramuscular injection<br>|
| Placebo Comparator: Placebo, ≥2 to <5 Years<br> | Other: Placebo<br>* Intramuscular injection<br>|
| Placebo Comparator: Placebo, ≥5 to <12 Years<br> | Other: Placebo<br>* Intramuscular injection<br>|
| Experimental: Low-Dose, ≥6 Months to <2 Years<br>Low-Dose (3mcg), 2 doses 21 doses apart | Biological: Biological/Vaccine: BNT162b2 3mcg<br>* BNT162b2 Low-Dose (3mcg) level<br>|
| Experimental: Low-Dose, ≥2 to <5 Years<br>Low-Dose (3mcg), 2 doses 21 days apart | Biological: Biological/Vaccine: BNT162b2 3mcg<br>* BNT162b2 Low-Dose (3mcg) level<br>|
| Experimental: High-Dose, 12 to <16 Years (Troponin I Testing)<br>High-Dose (30mcg), 3 doses | Biological: BNT162b2 30mcg<br>* BNT162b2 High-Dose (30mcg) level<br>|
| Experimental: Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)<br>Low/Mid-Dose (10mcg), 3 doses | Biological: Biological/Vaccine: BNT162b2 10mcg<br>* BNT162b2 Low/Mid-Dose (10mcg) level<br>|
| Experimental: Placebo, ≥5 to <12 Years (Troponin I Testing)<br> | Other: Placebo<br>* Intramuscular injection<br>|
| Experimental: Low-Dose, ≥6 Months to <2 Years (3-dose regimen)<br>Low-Dose (3mcg), 3 doses | Biological: Biological/Vaccine: BNT162b2 3mcg<br>* BNT162b2 Low-Dose (3mcg) level<br>|
| Experimental: Low-Dose, ≥2 to <5 Years (3-dose regimen)<br>Low-Dose (3mcg), 3 doses | Biological: Biological/Vaccine: BNT162b2 3mcg<br>* BNT162b2 Low-Dose (3mcg) level<br>|
| Placebo Comparator: Placebo, ≥6 Months to <2 Years (3-dose regimen)<br> | Other: Placebo<br>* Intramuscular injection<br>|
| Placebo Comparator: Placebo, ≥2 to <5 Years (3-dose regimen)<br> | Other: Placebo<br>* Intramuscular injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of participants in Phase 1 reporting local reactions | Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries. | for 7 days after Dose 1 and Dose 2 | 
| Percentage of participants in Phase 1 reporting systemic events | Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened join pain, decreased appetite drowsiness, and irritability as reported on electronic diaries | for 7 days after Dose 1 and Dose 2 | 
| Percentage of participants in Phase 1 reporting adverse events | As elicited by investigational site staff | from Dose 1 through 1 month after the last dose | 
| Percentage of participants in Phase 1 reporting serious adverse events | As elicited by investigational site staff | from Dose 1 through 6 months after the last dose | 
| Percentage of participants in Phase 2/3 reporting local reaction | Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries. | for 7 days after Dose 1 and Dose 2 | 
| Percentage of participants in Phase 2/3 reporting systemic events | Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain, decreased appetite, drowsiness, and irritability as reported on electronic diaries | for 7 days after Dose 1 and Dose 2 | 
| Percentage of participants in Phase 2/3 reporting adverse events | As elicited by investigational site staff | from Dose 1 through 1 month after the last dose | 
| Percentage of participants in Phase 2/3 reporting serious adverse events | As elicited by investigational site staff | from Dose 1 through 6 months after the last dose | 
| Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study | As measured at the central laboratory | 1 month after the second dose | 
| Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study | As measured at the central laboratory | 1 month after the second dose | 
| Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 in C4591001 study | As measured at the central laboratory | 1 month after the second dose | 
| In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study | As measured at the central laboratory | 1 month after the second dose | 
| In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study | As measured at the central laboratory | 1 month after the second dose | 
| In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 | As measured at the central laboratory | 1 month after the second dose | 
| Ph 2/3 selected-dose (3-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 years after 2 doses | As measured at the central laboratory | 1 month after the third dose | 
| Ph 2/3 selected-dose (3-dose), immunobridging SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 in study after 2 doses | As measured at the central laboratory | 1 month after the third dose | 
| In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study | As measured at the central laboratory | 1 month after the third dose | 
| In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 | As measured at the central laboratory | 1 month after the third dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs | As measured at the central laboratory | At each time point | 
| In evaluable Phase 2/3 participants at selected dose level in each age group, Geometric Mean Titers of SARS-CoV-2 neutralizing titers with no serological or virological evidence of past SARS-CoV-2 infection | As measured at the central laboratory | At baseline (before Dose 1) and 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2 | 
| In evaluable Phase 2/3 participants at the dose level selected in each age group, Geometric Mean Fold Ratio in SARS-CoV-2 serum neutralizing titer from before vaccination to each subsequent time point | As measured at the central laboratory | From before Dose 1 to each subsequent time point after Dose 2 | 
| Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to <12 years of age with successful immunobridging, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group | Per 1000 person-years of follow-up | From 7 days after the second dose to prior to third dose | 
| Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to <12 years of age with successful immunobridging, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group | Per 1000 person-years of follow-up | From 7 days after the second dose to prior to third dose | 
| Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥6 months to <5 years of age (3-dose series), evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group | 1000 person-years of follow-up | From 7 days after the third dose | 
| Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥6 months to <5 years of age (3-dose series), with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group | 1000 person-years of follow-up | From 7 days after the third dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Coronavirus Vaccine, SARS-CoV-2, RNA Vaccine, mRNA Vaccine